Monday, 15 April 2024

ECIO in Palma - An Ablation Lover's Guide

7:50

ECIO 2024 Is upon us! Back by popular demand are the highlights for those of us who eat, drink, and sleep percutaneous tumor ablation. Below are some CASCINATION highlights as well as the "cant-miss" sessions that you should put on your calendar

ECIO24Banner

First of all - we invite you to come by the CASCINATION booth and try something new - our AI Challenge - where participants can challenge themselves vs our AI-driven system to locate an invisible lesion, and assess an ablation zone versus the planned margin. 100 people worldwide have already competed and we are keeping tack of the high scores!

push-notification

If you are new to learning about Quality Ablation with CAS-One IR, a short video can be found here

Now, for the scientific congress highlights - of notable mention, are 7 abstracts featuring CAS-One IR

Transhepatic MWA of a metastasis in the adrenal gland

Multiprobe cryoablation of a recurrent RCC

Ablation of two metastasis in segment VIII

Advancing stereotactic ablation with AI: An evaluation of a novel segmentation took in a Spanish hospital setting

Developing a successful stereotactic ablation service

Accessing a high liver dome lesion close to the heart with stereotactic navigated ablation

Successful treatment of 3 CRC liver metastases with stereotactic MWA and IRE

It is very challenging to make a "short list" of sessions, but below are the ones that made our cut - we hope you set some calendar reminders for yourself to attend

Sunday April 28th

TB 141 - Why an IO should be on the tumor board: HCC
15:00-16:30 Auditorium 1

141.1 How far have we gotten with Ablation - D. Filippiadis

CF 143 - Meet the PI: upcoming research
15:00-16:30 Auditorium 3 - Moderators: R. Reimer, K. Chapiro

143.6 PROMETHEUS study: a prospective multicenter study on quantitative analysis of ablation margins in HCC - M. Burgmans

CF 151 -Intrahepatic cholangiocarcinoma: what IRs need to know?
17:00-18:30 Auditorium 1 - Moderators: B. Guiu, T. Greten

151.4 Ablation: a place in small ICCs? - B. Odisio

CF 152 -Selecting my best first case: why, when, how
17:00-18:30 Auditorium 2 - Moderators: R. Iezzi, E. Coimbra

152.2 Electrochemotherapy in liver lesions - A. Kovacs

BC 153 - Kidney and adrenal: renal ablation basics 1
17:00-18:30 Auditorium 2 - Moderators: R. Iezzi, E. Coimbra

153.1 Epidemiology: when to treat and when not to treat - M. Muntener
153.2 Biopsy of small renal masses: when and how best done? - L. Tselikas
153.3 Percutaneous renal ablation: best ablation tool and image guidance - R. Cazzato
153.4 Understanding the current outcome data compared to surgery - M. Calandri

Monday April 29th

CF 211 - Colorectal cancer liver metastases
8:30-10:00 Auditorium 1 - Moderators: A. Cervantes, M. Meijerink

211.1 ESMO guidelines explained: chemo before, after, or not at all for locally treatable disease - A. Cervantes
211.2 Can tumor biology teach us about the best multimodal treatment for oligometastatic disease? D. Arnold
211.3 When to ablate resectable colorectal cancer liver metastases? - M. Meijerink
211.4 When to resect ablatable colroectal cancer liver metastases? U. Cillo
211.5 When to offer SBRT instead of thermal ablation or resection? M. Mayinger

CF 242 Non-small lung cell cancer in 2024
15:00-16:30 Auditorium 2 - Moderators: R. Suh, J. Palussiere

242.4 The role of percutaneous ablation in NSCLC - R. Suh

TB 251 - Why an IO should be on the tumor board- lung
17:00-18:30 Auditorium 1 - Moderators: U. Martens, M. Alireza Hoda

251.1 How do you select the best thermal ablation technique - T. Iguchi
251.2 How to deal with multiple tumors - A. Veltri
251.3 A Review of frequent and rare complications - J. Gaubert

BC 253 - Kidney and adrenal: renal ablation basics 2

15700-19:00 Auditorium 3 - Moderators: G. Schmidt, X Buy

253.1 Follow up imaging after thermal ablation - G. Tsoumakidou
253.2 T1b renal tumor: is there a role for IO? - F. Ridouani
253.3 Complications of renal thermal ablation: how to avoid and manage them - G. Schmidt
253.4 Role of IO in oligometastatic renal cancer - X. Buy

Tuesday April 30th

CF311 - Open debates in modern HCC treatment

8:30-10:00 Auditorium 1 - Moderators: D. Arnold, P. Pereira

311.6 AI and HCC: A happy marriage? M. Ronot

CF312 - MSK IO: ablate, palliate and protect

8:30-10:00 Auditorium 2 - Moderators: M. Callstrom, A. Ryan

312.1 Heat-bsed thermal ablation of osseous malignancy - C. Pusceddu
312.2 Cryoablation of musculoskeletal tumors - R. Cazzato
312.3 Electrochemotherapy: current status and role - F. Deschamps

TB 321 - Why an IO should be on the tumor board: renal cancer

10:30-12:00 Auditorium 1 - Moderators: D. Breen, M. Schmidinger

321.1 Renal cancer ablation: complex decision-making - A. Barnacle

CF 322 - Artificial intelligence for interventional oncology

10:30-12:00 - Moderators F. Gomez Munoz, L. Marti-Bonmati

322.1 AI Basics: what the IO should know - B. Meyer
322.2 The role of image repositories for research on interventional oncology - L. Marti-Bonmati
322.3 Natural language processing in interventional oncology - A. Jimenez-Pastor
322.4 Artificial intelligence in patient selection and treatment planning in interventional oncology - J. Chapiro
322.5 Artificial intelligence in clinical and imaging follow up - R. Beets-Tan

SP 323 - Technical developments and clinical results in the treatment of liver tumors

10:30 - 12:00 Auditorium 3 - Moderators: R. Iezzi, A. Denys

323.3 AI-based ablation zone segmentation for ablative margin assessment during thermal ablation of colorectal liver metastasis: development and initial evaluation - C. Overduin
323.4 Validation of a Mathematic 3D-liver model to Predict the Most Suitable Treatment Option for Colorectal Liver Metastases: Recommendations from the COLLISION and COLDFIRE trial Expert Panel - B. Van den Bemd

CF 343 - Targeting tumors and assessing the results of the treatment

15:00-16:30 Auditorium 3 - Moderators L. Kenny, A. Adam

343.3 How I plan, deliver, and evaluate the technical success of the treatment of large tumors - C. Sofocleous
343.4 Stereotactic thermal ablation: a luxury for the few or a tool for everyone? - R. Bale

BC 353 - Kidney and adrenal ablation

17:00-19:00 Auditorium 3 - Moderators: J. Rivers, X. Buy

353.1 Indications and patient selection for benign and malignant adrenal tumors - R. Grasso
353.2 Technique for adrenal ablation - P. Rao
353.3 Medical environment for adrenal ablation: the anesthesiologist's point of view - J. Rives

Wednesday May 1st

TB 411 - Why an IO should be on the tumor board: metastatic colorectal cancer

8:30-10:00 - Moderators L. Tselikas, M. Meijierink

411.1 The ESMO guidelines - what is missing?
411.2 Resectable vs. potentially resectable lesions - S. Staettner
411.3 IO: first choice or conversion therapy - C. Sofocleous

Good luck trying to prioritize all of these exciting sessions! We will see you there.